Case Details
- Citation: [2015] SGHC 5
- Title: Allergan, Inc and another v Ferlandz Nutra Pte Ltd
- Court: High Court of the Republic of Singapore
- Date of Decision: 13 January 2015
- Case Number: Suit No 34 of 2013 (Summons No 5175 of 2014)
- Coram: George Wei JC
- Judgment Reserved: Yes
- Applicant/Plaintiffs: Allergan, Inc and another
- Respondent/Defendant: Ferlandz Nutra Pte Ltd
- Counsel for Plaintiffs: Alban Kang Choon Hwee and Oh Pin-Ping (ATMD Bird & Bird LLP)
- Defendant Representation: Defendant in person
- Officer Proposed to Act: Mr Lee Boon Guan (sole director and shareholder of the defendant)
- Legal Area: Civil Procedure — Representation of companies
- Procedural Provision: Order 1 rule 9(2) of the Rules of Court
- Related Procedural Provision: Order 1 rule 9(4) of the Rules of Court
- Primary Representation Rule: Order 5 rule 6(2) of the Rules of Court
- Statutes Referenced: Legal Profession Act; Rules of Court; Supreme Court of Judicature Act; Trade Marks Act; and the LATISSE (as the relevant trademark)
- Key Substantive Claims in the Suit: Trade mark infringement, passing off, injurious falsehood; counterclaim for groundless threats under s 35 of the Trade Marks Act
- Earlier Interlocutory Context: Former solicitors discharged on 22 August 2014; trial fixed for end-November 2014; affidavits of evidence-in-chief already filed
- Length of Judgment: 13 pages, 7,632 words
- Other Relevant Case in the Judgment: Bulk Trading SA v Pevensey Pte Ltd and another [2014] SGHC 236
- Cases Cited: [2014] SGHC 236; [2015] SGHC 5
Summary
Allergan, Inc and another v Ferlandz Nutra Pte Ltd [2015] SGHC 5 is a High Court decision concerning the procedural gateway for a company to obtain leave for an officer to act in legal proceedings without a solicitor. The defendant, a limited exempt private company, sought leave under O 1 r 9(2) of the Rules of Court for its sole director and shareholder, Mr Lee Boon Guan, to act on its behalf in an ongoing suit involving trade mark infringement, passing off, and injurious falsehood. The application arose after the defendant’s former solicitors discharged themselves, leaving the defendant without legal representation.
The court’s analysis focused on two issues: first, whether the defendant complied with the procedural requirements for an O 1 r 9(2) application, including the content expected in supporting affidavits under O 1 r 9(4); and second, whether the court should exercise its discretion to grant leave in the circumstances. Although the plaintiffs did not oppose the application in principle, the court emphasised that leave is not granted as a matter of course and that the court retains control over the exercise of discretion.
What Were the Facts of This Case?
The underlying suit concerned intellectual property and consumer-facing representations. The first plaintiff, Allergan, Inc, is an American pharmaceutical corporation that manufactures an eyelash-growth product used to treat hypotrichosis, a medical condition characterised by inadequate hair growth. The product is marketed under the LATISSE trademark. The LATISSE trademark is registered in Singapore under the Trade Marks Act in Class 5 for “pharmaceutical preparations used to treat eyelashes”. The first plaintiff is the registered proprietor, and the second plaintiff is its subsidiary and distributor in Singapore. The plaintiffs claimed use of the LATISSE trademark in Singapore since January 2011.
The defendant, Ferlandz Nutra Pte Ltd, is a limited exempt private company incorporated in Singapore. Its business involves distributing “cosmeticeutical and neutraceutical” products. One of its products is an eyelash-growth product distributed under the LASSEZ trademark. The plaintiffs alleged that the defendant’s LASSEZ product infringed the LATISSE registered trademark and also amounted to passing off. The plaintiffs further pleaded injurious falsehood based on the defendant’s alleged distribution of a letter from the United States Food and Drug Administration (FDA). The plaintiffs’ case was that the letter created an impression that the plaintiffs’ product was risky, hazardous, and unsafe, notwithstanding that the safety issue had long been resolved with the FDA and that the product was the only FDA-approved treatment for hypotrichosis.
In response, the defendant denied trade mark infringement and passing off, including on the basis that the plaintiffs’ and defendant’s marks were dissimilar and conceptually different. The defendant also raised statutory defences connected with fair use and comparative advertising. For injurious falsehood, the defendant denied both the alleged distribution of the FDA letter and the alleged injurious meaning. Additionally, the defendant counterclaimed for groundless threats of suit under s 35 of the Trade Marks Act.
Procedurally, the writ was issued on 14 January 2013 with an endorsed statement of claim. The defence and counterclaim were filed on 6 February 2013. By the time of the O 1 r 9(2) application, the parties had already filed affidavits of evidence-in-chief in preparation for a trial fixed for end-November 2014. The pleadings and affidavits had been filed or conducted by the defendant’s former solicitors. Those solicitors discharged themselves from acting for the defendant on 22 August 2014, which triggered the need for the defendant to seek leave for an officer to act.
What Were the Key Legal Issues?
The High Court identified two main issues. First, whether the procedural requirements for an application under O 1 r 9(2) had been complied with. This included whether the supporting affidavits met the requirements set out in O 1 r 9(4) of the Rules of Court, which governs what must be addressed when seeking leave for an officer to act. The court treated compliance as a threshold matter, because the purpose of the rule is to ensure that the court has sufficient information to assess whether the company’s circumstances justify departing from the default position that companies must be represented by solicitors.
Second, the court had to decide whether it should exercise its discretion to grant leave for Mr Lee to act on behalf of the defendant in the suit. This discretionary inquiry required the court to consider the adequacy of the evidence, the company’s financial position, and whether the proposed representation by an officer would be appropriate in the context of the litigation already underway, including the stage of proceedings and the existence of affidavits of evidence-in-chief.
How Did the Court Analyse the Issues?
The court began by setting out the baseline rule on representation. Under O 5 r 6(2) of the Rules of Court, a company must be represented by a solicitor in legal proceedings. That requirement is expressly subject to O 1 r 9(2), which allows the court, on application by a company, to give leave for an officer of the company to act on the company’s behalf in any matter or proceeding. The court noted that the amended O 1 r 9(2) applies to matters or proceedings whether or not they were commenced on or after 1 May 2014, meaning that the rule’s procedural framework governed the application regardless of the suit’s commencement date.
On the procedural requirements, the court scrutinised the defendant’s affidavits. Mr Lee swore the First Affidavit in support of the O 1 r 9(2) application dated 8 October 2014. The affidavit stated that Mr Lee was a director and that he was duly authorised to make the affidavit on behalf of the defendant, and that he was authorised to make an affidavit in support of his own representation. However, the court found that the First Affidavit did not state why leave should be granted for Mr Lee to act. The only relevant exhibit was an ACRA report showing that Mr Lee was the sole shareholder and only named director, and that the corporate secretary was named as Goh Bee Kwan. The remainder of the First Affidavit contained allegations relating to the merits of the plaintiffs’ claim, which the court considered of little or no relevance to the narrow procedural question under O 1 r 9(2).
Because of these deficiencies, the court adjourned the hearing in chambers on 27 October 2014 to allow the defendant to file a further affidavit compliant with O 1 r 9(4). The court’s approach demonstrates that the evidential content required by the rule is not a mere formality; it is intended to assist the court in assessing whether the company genuinely requires officer representation and whether the officer is properly positioned to act. On 31 October 2014, the defendant filed the Second Affidavit affirmed by Ms Lee Lay Hong, the corporate secretary. This affidavit stated that Mr Lee had been the sole director and business manager since incorporation and had experience in pharmaceutical companies, and that the defendant had depleted its financial resources due to heavy legal expenses. It also referred to an exhibit purportedly a financial statement, but the court found it was actually a bank statement showing only $3,420.40 in the defendant’s UOB account as at 31 August 2014. The court further observed that there was no information on the timing of Ms Lee’s appointment as corporate secretary, and the ACRA report earlier identified a different corporate secretary (Goh Bee Kwan). The court therefore treated the evidence as incomplete and insufficiently substantiated.
At the resumed hearing on 10 November 2014, the court again adjourned to provide an opportunity for the defendant to explain Ms Lee’s position as corporate secretary and to provide evidence of impecuniosity and reasons for the application. On 14 November 2014, Mr Lee filed a Third Affidavit. This affidavit stated that Ms Lee was appointed corporate secretary on 1 November 2014 and exhibited an appointment letter signed by Mr Lee. The Third Affidavit also asserted that the defendant had depleted its financial resources due to heavy legal expenses and exhibited interim bills and discharge requests from the former solicitors. However, the court noted that much of the correspondence from the former solicitors to the defendant was heavily redacted, and critically, there was no evidence of any response from the defendant explaining why it was not putting the former solicitors into funds, whether due to lack of funds or other reasons. The court also observed that much of the Third Affidavit addressed matters irrelevant to the O 1 r 9(2) application, such as issues concerning witnesses and discovery, and allegations about the conduct of plaintiffs’ counsel in disclosure. This further reinforced the court’s view that the defendant’s affidavits were not properly focused on the procedural requirements.
Having examined the affidavits, the court then considered the discretionary aspect. The plaintiffs had maintained a neutral position and did not object in principle, but the court emphasised that the decision to grant leave lies with the court and that consent does not automatically entitle the defendant to officer representation. The court also highlighted the novelty of O 1 r 9(2) and the absence of local authorities on the applicable principles at the time. Accordingly, the court had earlier vacated trial dates pending its decision, signalling that the representation issue could materially affect case management and fairness.
A key development occurred when the High Court delivered its judgment in Bulk Trading SA v Pevensey Pte Ltd and another [2014] SGHC 236 on 24 November 2014. That decision addressed the principles applicable to an O 1 r 9(2) application “in extenso”. The court in Allergan therefore invited further submissions to address Bulk Trading. The plaintiffs’ solicitors wrote to the Supreme Court Registry agreeing with Bulk Trading, while Mr Lee raised issues relating to corporate ownership of the plaintiffs, which the court considered irrelevant to the O 1 r 9(2) application. The court’s reliance on Bulk Trading indicates that the discretionary inquiry under O 1 r 9(2) is structured and guided by established principles, rather than being purely fact-sensitive or ad hoc.
Although the provided extract truncates the remainder of the judgment, the analysis up to that point shows the court’s method: it treated compliance with O 1 r 9(4) as essential, assessed whether the evidence on corporate status and financial incapacity was credible and sufficiently supported, and rejected affidavit material that did not address the procedural purpose of the application. The court also maintained a firm stance that officer representation is an exception to the default solicitor representation rule, and therefore requires careful judicial scrutiny.
What Was the Outcome?
The extract does not include the final orders. However, the court’s detailed directions for further affidavits, its repeated adjournments, and its emphasis on the deficiencies in the evidence suggest that the court was prepared to refuse leave unless the defendant could satisfy both procedural compliance and the discretionary criteria. The court’s approach indicates that the outcome would turn on whether the defendant ultimately provided adequate reasons and evidence for officer representation consistent with O 1 r 9(4) and the principles in Bulk Trading.
For practitioners, the practical effect of the decision—whatever the final outcome—would be significant. If leave were granted, Mr Lee would be able to act for the defendant in the suit despite the absence of solicitors, affecting how pleadings, affidavits, and hearings would proceed. If leave were refused, the defendant would likely need to secure representation by a solicitor or face procedural consequences, including potential adjournments or inability to advance its case effectively.
Why Does This Case Matter?
Allergan v Ferlandz Nutra is important because it illustrates how Singapore courts interpret and apply the amended O 1 r 9(2) regime for corporate representation. The case underscores that the rule is not a procedural shortcut for companies that are dissatisfied with legal costs or simply prefer to litigate through an officer. Instead, it is a tightly controlled exception to the solicitor representation requirement in O 5 r 6(2), designed to address genuine circumstances where a company cannot obtain representation, while protecting the integrity of proceedings.
From a precedent and research perspective, the decision is also notable for its reliance on Bulk Trading SA v Pevensey Pte Ltd and another [2014] SGHC 236, which the court treated as the key authority setting out the principles for O 1 r 9(2) applications. Where Bulk Trading provides the framework, Allergan demonstrates the application of that framework to real-world affidavit evidence, including the court’s expectations regarding: (i) why leave should be granted; (ii) the officer’s corporate role and authority; (iii) the corporate secretary’s status where relevant; and (iv) the evidential basis for claiming impecuniosity (for example, bank statements alone may be insufficient without broader financial context and explanation).
Practically, the case offers clear guidance for lawyers advising corporate clients who anticipate difficulties in retaining counsel. Affidavits must be carefully drafted to comply with O 1 r 9(4), must be supported by relevant documentary evidence, and must directly address the reasons for the application. Courts may disregard affidavit material that focuses on the merits of the underlying dispute rather than the procedural requirements. Moreover, even where the opposing party does not object, the court will independently assess whether the statutory and procedural conditions justify the exceptional step of allowing an officer to act.
Legislation Referenced
- Rules of Court (Cap 322, R 5, 2014 Rev Ed) — Order 1 rule 9(2) and Order 1 rule 9(4)
- Rules of Court — Order 5 rule 6(2)
- Legal Profession Act
- Supreme Court of Judicature Act
- Trade Marks Act (Cap 332, 2005 Rev Ed)
- Trade Marks Act — Section 35 (groundless threats of suit)
- LATISSE (as the relevant trademark referenced in the underlying suit)
Cases Cited
- Bulk Trading SA v Pevensey Pte Ltd and another [2014] SGHC 236
- Allergan, Inc and another v Ferlandz Nutra Pte Ltd [2015] SGHC 5
Source Documents
This article analyses [2015] SGHC 5 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.